Filing Analysis
Candel Therapeutics, Inc. announced its financial results for the quarter ended June 30, 2026. The filing serves as a formal announcement of quarterly earnings via an attached press release.
📋 Key Facts
- Report date: August 13, 2026
- Reporting period: Quarter ended June 30, 2026
- The company is classified as an emerging growth company.
- Financial results were furnished via Exhibit 99.1.
Candel Therapeutics, Inc. held its Annual Meeting of Stockholders on June 23, 2026. The meeting resulted in the successful election of four Class II directors and the ratification of KPMG LLP as the independent auditor for fiscal year 2026.
📋 Key Facts
- Annual Meeting held on June 23, 2026.
- Four Class II directors elected: Edward J. Benz, Jr., Paul B. Manning, Maha Radhakrishnan, and Paul Peter Tak (to serve until the 2029 annual meeting).
- KPMG LLP ratified as independent registered public accounting firm for fiscal year ending December 31, 2026.
- Total outstanding voting common stock as of April 24, 2026: 73,270,239 shares.
Candel Therapeutics entered into a formal employment agreement with its Chief Financial Officer, Charles Schoch, on June 12, 2026. The agreement codifies his compensation, bonus structure, and severance terms.
📋 Key Facts
- Annual base salary set at $468,600.
- Target annual bonus is 40% of base salary.
- Severance for termination without 'cause' or for 'good reason' includes 9 months of base salary plus target annual bonus.
- Equity awards subject to time-based vesting will fully accelerate if terminated without cause or for good reason within a specific window (1 month before to 12 months after) of a change in control.
- Agreement includes standard confidentiality, non-competition, and non-solicitation clauses.
Candel Therapeutics presented extended follow-up data from its Phase 3 clinical trial of aglatimagene besadenovec for localized prostate cancer at the American Urological Association 2026 Annual Meeting. The company also hosted a live webcast to review the results with investors.
📋 Key Facts
- Presented Phase 3 clinical trial data for aglatimagene besadenovec on May 15, 2026.
- The data concerns localized prostate cancer treatment.
- Presentation occurred at the American Urological Association 2026 Annual Meeting.
- Included an investor presentation (Exhibit 99.1) and press release (Exhibit 99.2).
Candel Therapeutics, Inc. announced its financial results for the first quarter ended March 31, 2026. The disclosure was made via a press release furnished as an exhibit to the filing.
📋 Key Facts
- Financial results reported for the quarter ended March 31, 2026.
- Press release issued on May 14, 2026.
- The filing was made under Item 2.02 (Results of Operations and Financial Condition).
Candel Therapeutics entered into an underwriting agreement to sell 18,348,624 shares of common stock at $5.45 per share, raising approximately $93.5 million in net proceeds. The capital is intended to fund the commercialization of CAN-2409 for prostate cancer and Phase 3 clinical trials for lung cancer.
🚩 Red Flags
- Significant shareholder dilution resulting from the issuance of 18.3 million new shares.
- High concentration of capital usage on a single lead candidate (CAN-2409).
📋 Key Facts
- Offering of 18,348,624 shares of common stock at a public price of $5.45 per share.
- Underwriters include Citigroup Global Markets Inc., Cantor Fitzgerald & Co., and Stifel, Nicolaus & Company.
- Estimated net proceeds of $93.5 million, or $107.6 million if the 30-day over-allotment option for 2,752,293 shares is fully exercised.
- Company expects the new capital to extend its cash runway into the first quarter of 2028.
- Proceeds are specifically earmarked for CAN-2409 launch readiness, medical affairs, and Phase 3 trial costs in non-small cell lung cancer.
Candel Therapeutics entered into a $100 million royalty-based purchase and sale agreement with RTW Investments, LP, contingent on FDA approval of CAN-2409 for prostate cancer. The deal provides non-dilutive financing in exchange for tiered royalties on U.S. net sales, capped at $250 million total royalty payments. The company also disclosed preliminary cash of approximately $119.7 million as of December 31, 2025.
🚩 Red Flags
- Payment is entirely contingent on FDA approval — if CAN-2409 is not approved by a specified deadline, the $100M never materializes
- Royalty ratchet mechanism (4.67% to 6.67%) penalizes the company if sales underperform, increasing the effective cost of capital
- Full text of the Purchase Agreement is not yet filed — key terms around indebtedness covenants, closing conditions, and the exact FDA approval deadline are not disclosed
- Multiple 8-K items (five items) in a single filing, though most are procedural/cross-references
- Preliminary and unaudited cash figure ($119.7M) is subject to change upon completion of financial closing procedures
📋 Key Facts
- $100 million payment from RTW Investments upon FDA approval of CAN-2409 (aglatimagene besadenovec) for intermediate-risk and high-risk localized prostate cancer
- Tiered royalty structure: 4.67% on annual U.S. net sales up to $1 billion, 1.33% on sales exceeding $1 billion
- Royalty ratchet: 4.67% tier increases to 6.67% if annual net sales miss certain specified levels, with cure opportunity
- Royalty cap of $250 million in total payments to RTW Investments
- Buy-Out Option available upon change of control or product sale, with termination payments up to the $250M Royalty Cap
- Transaction contingent on FDA Approval occurring by a specified (undisclosed) date
- Preliminary unaudited cash and cash equivalents of approximately $119.7 million as of December 31, 2025
- Filed February 19, 2026; signed by CEO Paul Peter Tak, M.D., Ph.D.
- Company is an emerging growth company listed on Nasdaq Global Market
Candel Therapeutics, Inc. announced a virtual Research and Development (R&D) Day scheduled for December 5, 2025. The event is intended to provide an overview of the company's viral immunotherapy approach and oncology pipeline.
📋 Key Facts
- Event Date: December 5, 2025
- Event Time: 11:00 am – 1:45 pm ET
- Format: Virtual Research and Development (R&D) Day
- Content Focus: Viral immunotherapy approach and oncology-focused pipeline overview
- Presentation filed as Exhibit 99.1
Candel Therapeutics, Inc. announced its financial results for the quarter ended September 30, 2025. The filing serves as a formal notice of the release of quarterly earnings data.
📋 Key Facts
- Reporting period: Quarter ended September 30, 2025
- Report date: November 13, 2025
- The filing includes Exhibit 99.1 containing the full press release of financial results.
Candel Therapeutics entered into a $130 million multi-tranche loan facility with Trinity Capital Inc., securing the debt against substantially all company assets. The filing also includes an omnibus warrant amendment involving directors and positive interim clinical data for CAN-3110.
🚩 Red Flags
- High-interest debt (initial 10.25% floating) secured by substantially all company assets.
- Significant prepayment penalties and a 4.25% 'Exit Fee' on the principal amount at maturity/early termination.
- Strict financial covenants: if market cap < $550M, must maintain high cash pledges (up to 75% of debt) based on regulatory milestones.
- Delisting from Nasdaq is specifically listed as an event of default.
- Related-party warrant amendment involving directors and a release of claims.
📋 Key Facts
- Entered into a Loan and Security Agreement (LSA) for up to $130 million in total principal across four tranches.
- First Tranche of $50.0 million was drawn down on October 14, 2025.
- Interest rate is floating: the greater of WSJ Prime + 3.0% or 9.75% (initial rate 10.25%).
- The loan is secured by a first priority security interest in substantially all company assets.
- Lenders received warrants to purchase common stock at an exercise price of $5.89 per share.
- Warrant Amendment extended the expiration of existing warrants held by directors (Paul Manning and Chris Martell) to September 30, 2027.
- Cash and cash equivalents as of Sept 30, 2025, were $87.2 million.
- Announced positive interim phase 1b clinical trial data for CAN-3110 in recurrent glioblastoma.
Candel Therapeutics entered into a First Amendment to its Lease Agreement, extending the lease term for its Needham, MA headquarters through August 31, 2029. The amendment adjusts base rent and extends the commitment period by three years.
📋 Key Facts
- Lease extension from August 31, 2026, to August 31, 2029.
- Base rent starting September 1, 2026, will be $607,880 per year.
- Annual rent increases of $15,197 during the extended term.
- Premises consist of approximately 15,197 rentable square feet in Needham, MA.
Candel Therapeutics, Inc. announced its financial results for the quarter ended June 30, 2025. The filing serves as a formal announcement of quarterly earnings via an attached press release.
📋 Key Facts
- Reporting period: Quarter ended June 30, 2025
- Report date: August 14, 2025
- The company is classified as an emerging growth company.
Candel Therapeutics announced a registered direct offering of 3,221,395 shares at $4.67 per share, aiming to raise approximately $15 million in gross proceeds. The offering is being conducted via an existing shelf registration statement and includes participation from healthcare-focused institutional investors and company insiders.
🚩 Red Flags
- Dilution risk for existing shareholders due to the issuance of over 3.2 million new shares.
- Insider participation (officers and directors) in a direct offering can sometimes indicate limited external appetite at higher price points, though here it is priced at market close.
📋 Key Facts
- Offering Type: Registered direct offering of 3,221,395 shares of common stock.
- Price per Share: $4.67 (equal to the June 23, 2025 closing price).
- Gross Proceeds: Estimated at approximately $15.0 million before expenses.
- Expected Closing Date: June 25, 2025.
- Purchasers: Healthcare-focused institutional investors, executive officers, and directors of the Company.
Candel Therapeutics, Inc. has appointed Charles Schoch as its new Chief Financial Officer, effective June 20, 2025. Mr. Schoch transitions from his role as interim CFO to the permanent position.
📋 Key Facts
- Charles Schoch appointed as CFO effective June 20, 2025.
- Mr. Schoch has served as interim CFO since January 2024 and joined the company in November 2021.
- Annual base salary increased to $440,000 with a target annual bonus of 40% of base salary.
- Granted an option to purchase 50,000 shares of common stock with a 4-year vesting schedule (25% at one year, remainder over 36 months).
- Prior experience includes Corporate Controller at Corbus Pharmaceuticals and auditor at PwC.
Candel Therapeutics, Inc. held its Annual Meeting of Stockholders on June 17, 2025. The meeting resulted in the successful election of three Class I directors and the ratification of KPMG LLP as the independent auditor.
🚩 Red Flags
- High number of 'Broker Non-Votes' across all director elections (e.g., 16,655,944 for each nominee), suggesting a significant portion of the shareholder base did not vote on these specific items.
📋 Key Facts
- Annual Meeting held on June 17, 2025.
- Three Class I directors elected: Renee Gaeta, Gary J. Nabel, M.D., Ph.D., and Joseph C. Papa, R.Ph., M.B.A., to serve three-year terms expiring in 2028.
- KPMG LLP ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2025.
- As of April 21, 2025, there were 49,269,668 outstanding shares of voting common stock.
Candel Therapeutics, Inc. announced the appointment of Maha Radhakrishnan, M.D., to its Board of Directors, increasing the board size from nine to ten members.
📋 Key Facts
- Maha Radhakrishnan, M.D., appointed to the Board effective June 4, 2025.
- Board size increased from nine (9) to ten (10) directors.
- Dr. Radhakrishnan will receive an option to purchase 28,480 shares of common stock, vesting over three years in equal monthly installments.
- Dr. Radhakrishnan previously served as Group Senior Vice President and Chief Medical Officer at Biogen Inc.
Candel Therapeutics announced that the FDA has granted Regenerative Medicine Advanced Therapy (RMAT) designation to its lead immunotherapy candidate, CAN-2409. This designation is for the treatment of newly diagnosed localized prostate cancer in patients with intermediate-to-high-risk disease.
📋 Key Facts
- FDA granted RMAT designation to CAN-2409 (aglatimagene besadenovec) on May 28, 2025.
- Target indication: Newly diagnosed localized prostate cancer in patients with intermediate-to-high-risk disease.
- CAN-2409 is the Company's biological immunotherapy lead candidate.
Candel Therapeutics announced that positive Phase 3 clinical trial results for its candidate CAN-2409 in localized prostate cancer will be presented at the 2025 ASCO Annual Meeting. The trial met both primary and secondary endpoints, showing a statistically significant improvement in disease-free survival.
📋 Key Facts
- Phase 3 clinical trial of aglatimagene besadenovec (CAN-2409) for intermediate-to-high-risk localized prostate cancer met primary and secondary endpoints.
- Demonstrated statistically significant improvement in disease-free survival with a p-value of 0.0155.
- Reported a 30% reduction (HR 0.7) in the risk for prostate cancer recurrence or death due to any cause.
- Trial sample size: n=496 for CAN-2409 group vs. n=249 for placebo group.
- Results will be presented at the ASCO Annual Meeting (May 30 - June 3, 2025) in Chicago, IL.
Candel Therapeutics, Inc. filed an 8-K to announce its financial results for the quarter ended March 31, 2025. The filing serves as a formal announcement of quarterly earnings and includes a press release as Exhibit 99.1.
📋 Key Facts
- Reporting period: Quarter ended March 31, 2025
- Filing date: May 13, 2025
- The report contains results of operations and financial condition under Item 2.02.
- Press release issued as Exhibit 99.1.
Candel Therapeutics announced that an abstract for its Phase 3 clinical trial of CAN-2409 was accepted for an oral presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. The presentation will focus on data regarding patients with intermediate-to-high risk localized prostate cancer.
📋 Key Facts
- Oral presentation accepted for the 2025 ASCO Annual Meeting (May 30 to June 3, 2025).
- Presentation features Phase 3 clinical trial data for CAN-2409.
- Target patient population: intermediate-to-high risk localized prostate cancer.
Candel Therapeutics announced positive final survival data from its Phase 2a clinical trial of CAN-2409 in patients with advanced non-small cell lung cancer (NSCLC) who had inadequately responded to immunotherapy. The results showed significant long-term survival, particularly in patients with non-squamous histology.
📋 Key Facts
- Phase 2a trial data for CAN-2409 in stage III/IV NSCLC patients showing a median overall survival (mOS) of 24.5 months in the Cohort 1+2 group (n=46).
- In patients with progressive disease despite ICI treatment, mOS was 21.5 months, compared to 9.8–11.8 months reported in literature for standard docetaxel chemotherapy.
- 37% of patients with progressive disease were still alive 2 years after administration as of the March 2, 2025 data cut.
- Non-squamous histology showed superior outcomes: mOS of 25.4 months in patients with progressive disease (n=33) and an exploratory ITT analysis mOS of 16.7 months.
- Observed 'abscopal effect' in 69% of patients with multiple lesions, where uninjected tumors decreased in size.
- Company plans to prepare for a potentially registrational clinical trial focusing on non-squamous NSCLC histology.
Candel Therapeutics, Inc. announced its financial results for the fiscal quarter and year ended December 31, 2024, on March 13, 2025.
📋 Key Facts
- Reporting period: Quarter and Year ended December 31, 2024.
- Announcement date: March 13, 2025.
- The filing includes the announcement of financial results via a press release (Exhibit 99.1).
Candel Therapeutics announced positive final overall survival data from its Phase 2 clinical trial of CAN-2409 for non-metastatic pancreatic cancer. The data showed significantly prolonged median overall survival in the treatment group compared to the control group.
📋 Key Facts
- Median overall survival was 31.4 months for the CAN-2409 group (n=7) vs. 12.5 months for the control group (n=6).
- Median survival post-progression was 21.2 months in the treatment arm vs. 7.2 months in the control arm.
- Three out of seven patients in the CAN-2409 group were still alive at data cut-off, with survival reaching up to 66.0 months from enrollment.
- Previous 24-month analysis showed a 71.4% survival rate for CAN-2409 vs. 16.7% for the control group.
- Clinical data indicated robust immune response activation (CD8+ T cells, dendritic cells) in treated patients' tumor microenvironment.
- The regimen was reported as well-tolerated with no dose-limiting toxicities or cases of pancreatitis.
Candel Therapeutics issued a corporate update highlighting pipeline momentum for 2025 and reported an unaudited cash position of $102.9 million as of December 31, 2024.
🚩 Red Flags
- Cash position is unaudited and may differ materially from final year-end statements.
📋 Key Facts
- Unaudited cash position at December 31, 2024: $102.9 million.
- Company highlighted strong pipeline momentum from 2024.
- The reported cash amount is preliminary and subject to final financial closing procedures.
Candel Therapeutics announced a significant equity offering consisting of 10,000,001 common shares and up to 3,333,333 pre-funded warrants at $6.00 per share. The proceeds are intended to fund clinical development through Q1 2027.
🚩 Red Flags
- Significant dilution via the issuance of over 13 million new securities (shares + warrants).
- Use of pre-funded warrants is a common tactic in micro-cap financing to avoid certain regulatory hurdles but results in immediate equity dilution.
- The company explicitly notes that capital may be used sooner than expected and additional capital will be required for future development.
📋 Key Facts
- Offered 10,000,001 common shares at $6.00 per share.
- Offered up to 3,333,333 pre-funded warrants at $5.99 per warrant (exercise price of $0.01).
- Underwriters include Citigroup Global Markets Inc., BofA Securities, Inc., and Canaccord Genuity LLC.
- Estimated net proceeds: ~$74.7 million (base) to ~$86.0 million (if option is exercised).
- Expected closing date: On or about December 16, 2024.
- Proceeds intended for CAN-2409 BLA preparation and general corporate purposes.
Candel Therapeutics announced mixed clinical trial results for its CAN-2409 immunotherapy in prostate cancer. The Phase 3 trial met its primary endpoint with statistically significant improvements in disease-free survival, while the Phase 2b trial failed to reach statistical significance for its primary endpoints.
🚩 Red Flags
- Phase 2b clinical trial failed to meet primary endpoints, limiting the immediate market application of CAN-2409.
- Binary outcome risk: The company's valuation is now heavily tied to the regulatory success of a single indication (intermediate-to-high risk).
📋 Key Facts
- Phase 3 trial (intermediate-to-high risk) met primary endpoint: Statistically significant improvement in DFS (p=0.0155; HR 0.7).
- Observed a 14.5% relative improvement in DFS at 54 months for the treatment arm vs. placebo.
- Phase 3 showed highly significant effect on prostate cancer-free survival (p=0.0046; HR 0.6) in specific analysis.
- 80.4% pathological complete responses observed in Phase 3 treatment arm vs. 63.6% in control (p=0.0015).
- Phase 2b trial (low-to-intermediate risk) did not meet its primary endpoint, showing only numerical rather than statistical improvement.
- Company plans to initiate FDA discussions and anticipates a Biologics License Application (BLA) submission in Q4 2026.
Candel Therapeutics, Inc. announced its financial results for the quarter ended September 30, 2024. The filing serves as a formal announcement of quarterly earnings via an attached press release.
📋 Key Facts
- Reporting period: Quarter ended September 30, 2024
- Filing date: November 14, 2024
- The report includes results of operations and financial condition under Item 2.02.
- Financial statements are provided in Exhibit 99.1.
Candel Therapeutics released clinical safety and tolerability data from its Phase 1b trial of CAN-3110 for recurrent high-grade glioma (rHGG). The company reported improved survival in the multiple injection cohort and noted evidence of radiologic pseudo-progression in biopsy samples.
🚩 Red Flags
- Clinical-stage biotech risk: Survival data is based on a very small sample size (n=6).
📋 Key Facts
- Presented safety/tolerability data from the multiple injection cohort of Phase 1b CAN-3110 trial at the 2024 International Oncolytic Virotherapy Conference.
- Observed improved survival: 3 out of 6 patients in the rHGG cohort were alive >1 year post-treatment (survival times: 12.2, 13.0, and 18.7 months).
- Biopsy data suggested radiologic pseudo-progression, showing a near absence of tumor cells alongside dense lymphocyte infiltrates despite MRI enhancement.
- Data was presented as part of Item 7.01 (Regulation FD Disclosure) and is considered 'furnished' rather than 'filed'.
Candel Therapeutics, Inc. filed an 8-K to announce its financial results for the quarter ended June 30, 2024. The filing serves as a formal notice that earnings data is being furnished via a press release.
📋 Key Facts
- Report date: August 13, 2024
- Reporting period: Quarter ended June 30, 2024
- The filing includes Exhibit 99.1 containing the full text of the press release.
- The information is furnished but not 'filed' for purposes of Section 18 of the Exchange Act.
Candel Therapeutics held its Annual Meeting of Stockholders on June 26, 2024. The meeting resulted in the successful election of three Class III directors and the ratification of KPMG LLP as the company's independent auditor.
📋 Key Facts
- Annual Meeting held on June 26, 2024.
- Three Class III directors elected: Nicoletta Loggia, Ph.D., R.Ph., Christopher Martell, and Diem Nguyen, Ph.D., M.B.A., for three-year terms expiring in 2027.
- KPMG LLP ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2024.
- As of May 15, 2024, there were 29,756,005 outstanding shares of voting common stock.
Candel Therapeutics, Inc. amended its bylaws to significantly reduce the quorum requirement for stockholder meetings. The amendment changes the required quorum from a majority of shares entitled to vote to one-third of shares entitled to vote.
🚩 Red Flags
- Reduction in quorum requirements can make it easier for minority shareholders or activist investors to push through actions with lower participation levels.
📋 Key Facts
- Bylaws Amendment approved by the Board of Directors on May 29, 2024.
- Amendment reduces quorum requirement for all stockholder meetings from a majority to one-third (33.3%) of shares entitled to vote.
- The amendment is effective immediately as of May 29, 2024.
Candel Therapeutics announced positive topline phase 2 clinical trial data for CAN-2409 in patients with advanced non-small cell lung cancer (NSCLC) who had previously failed immune checkpoint inhibitor therapy. The data showed improved median overall survival and systemic immune response compared to standard of care.
📋 Key Facts
- Phase 2 trial data cut-off: April 1, 2024.
- Median overall survival (mOS) was 20.6 months for patients receiving CAN-2409 plus valacyclovir, compared to a published mOS of 11.6 months with docetaxel-based chemotherapy in similar populations.
- mOS across all patients who had an inadequate response to ICI therapy (n=46) was 22.0 months.
- 71.4% of metastatic disease patients (n=35) experienced a beneficial effect on both injected and uninjected tumors (abscopal response).
- Safety profile: No dose-limiting toxicities or grade 4+ treatment-related adverse events reported; most were grade 1 or 2.
- Data to be presented at the 2024 ASCO Annual Meeting on June 3, 2024.
Candel Therapeutics, Inc. announced its financial results for the quarter ended March 31, 2024. The filing serves as a formal announcement of quarterly earnings via an attached press release.
📋 Key Facts
- Reporting period: Quarter ended March 31, 2024
- Announcement date: May 14, 2024
- The report includes results of operations and financial condition under Item 2.02.
Candel Therapeutics announced upcoming poster presentations at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting. The company will present data regarding its CAN-3110 phase 1 trial and topline overall survival data from its CAN-2409 phase 2 clinical trial.
📋 Key Facts
- Company to present at the 2024 ASCO Annual Meeting (May 31 to June 4, 2024) in Chicago, IL.
- Presentation 1: Phase 1 data for CAN-3110 in recurrent high-grade glioma (Cohort C), focusing on feasibility and tolerability of multiple injections.
- Presentation 2: Topline overall survival data from phase 2 trial of CAN-2409 plus valacyclovir, combined with immune checkpoint inhibitors, for non-resectable stage III/IV NSCLC.
Candel Therapeutics announced that the FDA has granted Orphan Drug Designation for its candidate CAN-2409 intended for the treatment of pancreatic cancer.
📋 Key Facts
- FDA granted Orphan Drug Designation for CAN-2409 on April 11, 2024.
- The designation is specifically for the treatment of pancreatic cancer.
- The announcement was made via press release under Item 7.01 and Item 8.01.
Candel Therapeutics announced the development of a second candidate from its enLIGHTEN™ Discovery Platform, which showed promise in inducing tertiary lymphoid structures (TLS) in mouse models. The company will present this data at the American Association for Cancer Research Annual Meeting.
📋 Key Facts
- Announced a new first-in-class multimodal immunotherapy candidate targeting TLS induction.
- The candidate was developed using the enLIGHTEN™ Advanced Analytics suite applied to immune checkpoint inhibitor-treated datasets.
- In mouse models, the payload combinations showed TLS induction, monotherapy anti-tumoral activity, and enhanced responses when combined with anti-PD-1 therapy.
- Data presentation scheduled for the American Association for Cancer Research Annual Meeting on April 9, 2024.
Candel Therapeutics announced positive interim data from its randomized Phase 2 clinical trial of CAN-2409 for non-metastatic pancreatic cancer. The data indicates significantly improved overall survival rates compared to the control group.
📋 Key Facts
- Interim data cut-off date: March 29, 2024.
- Estimated median overall survival (OS) in CAN-2409 group was 28.8 months vs. 12.5 months in the control group for borderline resectable PDAC (n=13).
- At 24 months, survival rate was 71.4% for CAN-2409 patients vs. 16.7% for control.
- At 36 months, estimated survival rate was 47.6% for CAN-2409 patients vs. 16.7% for control.
- Observed robust immune response including dense aggregates of CD8+ granzyme B positive cytotoxic tumor infiltrating lymphocytes in treated patients.
- Safety profile reported as favorable with no dose-limiting toxicities or cases of pancreatitis.
Candel Therapeutics, Inc. announced its financial results for the fiscal quarter and year ended December 31, 2023. The filing serves as a formal announcement of quarterly earnings via an attached press release.
📋 Key Facts
- Reporting period: Quarter and Year ended December 31, 2023.
- Announcement date: March 28, 2024.
- The filing includes Exhibit 99.1 containing the full text of the press release regarding financial results.
Candel Therapeutics announced its intention to present a poster at the upcoming American Association for Cancer Research (AACR) Annual Meeting. The presentation will focus on a candidate from their enLIGHTEN™ Discovery Platform regarding immunotherapy strategies for solid tumors.
📋 Key Facts
- Company will present a poster at the AACR Annual Meeting in San Diego, CA.
- Meeting dates: April 5-10, 2024.
- Topic: Second candidate from the enLIGHTEN™ Discovery Platform (multimodal immunotherapy for induction of tertiary lymphoid structures).
- The disclosure is made under Item 7.01 (Regulation FD Disclosure) and is not considered 'filed' for liability purposes.
Candel Therapeutics announced that the FDA has granted Fast Track Designation for its lead product candidate, CAN-3110. This designation is intended to expedite the development and review of an immunotherapy treatment for recurrent high-grade glioma.
📋 Key Facts
- FDA granted Fast Track Designation for CAN-3110 on February 13, 2024.
- CAN-3110 is an investigator-sponsored HSV-1 oncolytic viral immunotherapy candidate.
- The target indication is the treatment of recurrent high-grade glioma to improve overall survival.
Candel Therapeutics announced the resignation of CFO Jason A. Amello and the appointment of Charles Schoch as interim CFO, effective January 12, 2024.
🚩 Red Flags
- Departure of the Chief Financial Officer (CFO) can sometimes signal internal friction or disagreements regarding financial reporting/strategy.
📋 Key Facts
- Jason A. Amello resigned as CFO, principal financial officer, and principal accounting officer on January 12, 2024.
- Charles Schoch appointed as interim CFO, principal financial officer, and principal accounting officer effective January 12, 2024.
- Schoch previously served as VP of Finance and Corporate Controller since March 2023.
- Schoch's annual base salary increased to $325,000 during his interim tenure.
Candel Therapeutics announced that it has successfully regained compliance with Nasdaq's minimum bid requirement. The company had previously been notified of non-compliance after its stock closed below $1.00 for 30 consecutive business days.
🚩 Red Flags
- Historical price volatility/weakness that led to a potential delisting threat (stock trading below $1.00).
📋 Key Facts
- The Company was in violation of Nasdaq Listing Rule 5450(a)(1) regarding the $1.00 minimum bid requirement.
- Nasdaq notified the company on November 15, 2023, that it had 180 days to regain compliance.
- As of December 28, 2023, Nasdaq confirmed the Company has regained compliance.
- The delisting matter is officially considered closed by the Nasdaq Staff.